Author:
Tu Chien-Lung,Wang Yi-Lin,Hu Teh-Min,Hsu Li-Feng
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference48 articles.
1. Yu B. Greater potential cost savings with biosimilar use. Am J Manag Care. 2016;22(5):378.
2. Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.
3. Grewal S, Ramsey S, Balu S, Carlson JJ. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim. Expert Rev Pharmacoecon Outcomes Res. 2018;18(4):447–54.
https://doi.org/10.1080/14737167.2018.1476142
.
4. Kurki P. Potential changes to the FDA approach to biosimilars have a global impact. GaBI J. 2018;7(2):53–8.
5. EMA. Guideline on similar biological medicinal products. 2014.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
. Accessed 16 Feb 2019.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献